

Qiagen to acquire Parse Biosciences for \$225 million

written by CAP TODAY
November 6, 2025

Nov. 6, 2025—[Qiagen](#) has entered into a definitive agreement to fully acquire Parse Biosciences, a provider of scalable, instrument-free solutions for single-cell research, for \$225 million. The acquisition will expand Qiagen's Sample technologies portfolio into the single-cell sequencing market with highly scalable chemistry designed to power research involving millions of billions of cells, according to a press release from Qiagen. Parse's scalable chemistry is also expected to accelerate growth in Qiagen's digital insights bioinformatics business.

"Single-cell analysis is the key to understanding health and disease at a mechanistic level. By combining Parse with our Sample technologies portfolio and QDI bioinformatics offering, we can provide researchers with the tools to generate the massive data sets required to build predictive virtual cell models that fuel AI-based drug discovery," Thierry Bernard, CEO of Qiagen, said in the release.

The transaction is expected to be completed next month.